Search results for "HEPATITIS C"

showing 10 items of 820 documents

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

2018

OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals’ opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on tr…

AdultAged 80 and overLiver CirrhosisMaleConsensusGenotypedelphi methodhepatitis c virus; direct-acting antivirals; delphi method; consensus; adult; aged 80 and over; antiviral agents; consensus; elasticity imaging techniques; female; genotype; hepacivirus; hepatitis c chronic; humans; liver cirrhosis; male; middle aged; surveys and questionnairesHepacivirushepatitis c virusHepatitis C ChronicMiddle AgedAntiviral AgentschronicagedSurveys and QuestionnairesHCV80 and overElasticity Imaging TechniquesHumansFemalehepatitis cdirect-acting antiviralsEuropean review for medical and pharmacological sciences
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.

2010

Metabolic factors have been associated with liver damage in patients with genotype 1 chronic hepatitis C (G1 CHC). We tested visceral adiposity index (VAI), a new marker of adipose dysfunction in G1 CHC, patients to assess its association with host and viral factors and its link to both histological findings and sustained virological response (SVR). Two hundred thirtysix consecutive G1 CHC patients were evaluated by way of liver biopsy and anthropometric and metabolic measurements, including insulin resistance (IR), homeostasis model assessment (HOMA), and VAI using waist circumference, body mass index, triglycerides, and highdensity lipoprotein cholesterol. All biopsies were scored by one …

AdultBlood GlucoseMalemedicine.medical_specialtyPathologyAlcohol DrinkingGenotypeInterferon alpha-2Intra-Abdominal FatGastroenterologyAntiviral AgentsBody Mass IndexPolyethylene GlycolsInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHepatologymedicine.diagnostic_testbusiness.industryCholesterol HDLInterferon-alphaAlanine TransaminaseHepatitis CHepatologyHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseRecombinant ProteinsFatty LiverDiabetes Mellitus Type 2Liver biopsyHypertensionRNA ViralFemaleSteatosisWaist CircumferencebusinessViral loadBody mass indexHepatology (Baltimore, Md.)
researchProduct

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

2013

SUMMARY. Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate…

AdultCD36 AntigensMaleGenotypeBiopsyEnzyme-Linked Immunosorbent AssayLIVER FIBROSISHepacivirusCHRONIC HEPATITIS CAntigens CD36Settore MED/08 - Anatomia PatologicaAntiviral AgentsSeverity of Illness IndexPlasmaRibavirinHumansHEPATIC STEATOSISAgedSettore MED/12 - GastroenterologiaHepatitis C ChronicMiddle AgedFatty LiverLiverBiological MarkersFemaleInterferonsCD36 HCV steatosisBiomarkersINSULIN RESISTANCE
researchProduct

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

2012

Background & Aims Microparticles released into the bloodstream upon activation or apoptosis of CD4+ and CD8+ T cells correlate with inflammation as determined by histologic analysis in patients with chronic hepatitis C (CHC). Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver. Methods We compared profiles of circulating microparticles from patients with NAFL and NASH (n = 67) to those of CHC (n = 42), with healthy individuals (controls) using flow cytometry; the profiles were correlated with inflammation grade and fibrosis stage based on histologic an…

AdultCD4-Positive T-LymphocytesLiver CirrhosisMaleLymphocyteBiologyCD8-Positive T-LymphocytesChronic liver diseaseSeverity of Illness IndexArticleCell-Derived MicroparticlesDiagnosis DifferentialImmune systemFibrosisCell-Derived MicroparticlesNon-alcoholic Fatty Liver DiseasemedicineHumansAgedAged 80 and overInflammationHepatologyFatty liverBiopsy NeedleGastroenterologyAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFlow CytometryFatty Livermedicine.anatomical_structureAlanine transaminaseLiverROC CurveCase-Control StudiesImmunologybiology.proteinLinear ModelsFemaleBiomarkersGastroenterology
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

C4BQ0: a genetic marker of familial HCV-related liver cirrhosis

2004

Source Department of Medicine and Pneumology, V Cervello Hospital, Via Trabucco 180, 90146 Palermo, Italy. lindpas@yahoo.it Abstract BACKGROUND AND METHODS: Host may have a role in the evolution of chronic HCV liver disease. We performed two cross-sectional prospective studies to evaluate the prevalence of cirrhosis in first degree relatives of patients with cirrhosis and the role of two major histocompatibility complex class III alleles BF and C4 versus HCV as risk factors for familial clustering. FINDINGS: Ninety-three (18.6%) of 500 patients with cirrhosis had at least one cirrhotic first degree relative as compared to 13 (2.6%) of 500 controls, (OR 7.38; CI 4.21-12.9). C4BQ0 was signifi…

AdultGenetic MarkersLiver Cirrhosismedicine.medical_specialtyCirrhosisAdolescentFamilial clusteringFamilial clusteringGastroenterologyLiver cirrhosiC4BQ0Liver diseaseInternal medicineHCV diffusionComplement C4bPrevalencemedicineHumansProspective StudiesAlleleFamily historyFirst-degree relativesMHC class III allelesChildProspective cohort studyAllelesAgedAged 80 and overHepatologybusiness.industryGastroenterologyHepatitis C ChronicMiddle Agedmedicine.diseaseCross-Sectional StudiesGenetic markerbusinessC4BQ0; Familial clustering; HCV diffusion; Liver cirrhosis; MHC class III allelesDigestive and Liver Disease
researchProduct

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a st…

1999

Abstract Background/Aims: Antibodies to cytochrome P450 2D6, also knownas LKM1-autoantibodies, are characteristic for a subgroup of patients with autoimmune hepatitis, but can also occasionally be found in hepatitis C. We observed the occurrence of LKM1-autoantibodies 4 months after liver transplantation for Wilson's disease, in close association with a steroid-resistant rejection episode, in the absence of evidence for autoimmune hepatitis or hepatitis C. Methods: Sera from several time points prior to and following transplantation were tested for LKM-reactivity by immunofluorescence, ELISA and Western blotting. Antigen specificity was confirmed by Western blotting analysis on different cy…

AdultGraft RejectionMaleTime Factorsmedicine.medical_treatmentPrednisoloneDrug ResistanceEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisLiver transplantationKidneyHepatolenticular DegenerationAntibody SpecificityAzathioprinemedicineHumansAutoantibodiesHepatitisHepatologybiologybusiness.industryStomachHepatitis Cmedicine.diseaseVirologyLiver TransplantationTransplantationWilson's diseaseCytochrome P-450 CYP2D6Immunologybiology.proteinCyclosporineAntibodyViral hepatitisbusinessImmunosuppressive AgentsJournal of hepatology
researchProduct

Liver transplantation: the Italian experience

2002

Abstract Background. Liver transplantation is the standard treatment for patients with end-stage liver disease no longer responsive to conventional medical treatment Aims . To report the longterm experience of liver transplantation in Italy. Patients and Methods . Data were obtained retrospective by means of a multiple-item form collected from 15 Italian liver transplant centres. The filing centre was centralized. Results . A total of 3323 liver transplants were performed on 3026 patients, with a cumulative proportional survival of 72.4%. Three, 5 and 10 years' patient survival rates were 72.3%, 68.8% and 61.3%, respectively. The most common indication for liver transplantation were hepatit…

AdultGraft RejectionMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisAdolescentmedicine.medical_treatmentLiver transplantationGastroenterologyLiver diseaseRecurrenceInternal medicinePrevalenceMedicineHumansAgedRetrospective StudiesLiver transplantationHepatologybusiness.industryLiver DiseasesPatient SelectionGastroenterologyHepatitis CHepatitis BMiddle Agedmedicine.diseaseTransplantationSurvival RateItalyFemaleHepatitis D virusbusinessLiver disease
researchProduct

Lipid peroxidation products and antioxidants in human disease.

1998

Lipid peroxidation (LPO) is a free radical-related process that in biologic systems may occur under enzymatic control, e.g., for the generation of lipid-derived inflammatory mediators, or nonenzymatically. This latter form is associated mostly with cellular damage as a result of oxidative stress, which also involves cellular antioxidants in this process. This article focuses on the relevance of two LPO products, malondialdehyde (MDA) and 4-hydroxynonenal (HNE), to the pathophysiology of human disease. The former has been studied in human serum samples of hepatitis C virus-infected adults and human immunodeficiency virus-infected children. In these two cases it is shown that the specific ass…

AdultHealth Toxicology and MutagenesisHIV InfectionsPharmacologyBiologymedicine.disease_causeAntioxidantsLipid peroxidationMicechemistry.chemical_compoundMalondialdehydemedicineAnimalsHumansDiseaseChildchemistry.chemical_classificationAldehydesGlutathione PeroxidaseGlutathione peroxidasePublic Health Environmental and Occupational HealthGlutathioneMalondialdehydeHepatitis CIn vitroPathophysiologyRatsOxidative StressEnzymechemistryImmunologyBlood VesselsLipid PeroxidationOxidative stressResearch ArticleEnvironmental Health Perspectives
researchProduct